Operates a multi-brand beauty and personal care platform in India, selling topical products directly to consumers through general trade, modern trade and e-commerce channels. The flagship Mamaearth brand, focused on natural and baby care, is sold across 200,000 retail outlets and grew in the mid-teens in FY26. The Derma Co, built around active-ingredient skincare, has reached ₹750 cr+ in annualised revenue with about 1% Nielsen share in the face wash category. Reginald Men, a men's grooming brand consolidated in FY26, doubled its revenue and crossed ₹100 cr in annualised revenue within its first quarter post-acquisition. Focus categories grew 35% year-on-year in FY26, contributing 500 basis points to overall mix. The company has entered nutraceuticals via a 58% stake in Fluence Pharma and added BTM Ventures at a 95% stake. Other operating expenses are the largest line on the cost sheet at 49.3% of revenue, and management has flagged raw and packaging material inflation as a near-term cost pressure addressed through Q1 FY27 calibrated price hikes. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Mamaearth (flagship natural and baby care brand), The Derma Co (active-ingredient skincare), Reginald Men (men's grooming), Younger brands (Aqualogica, BBlunt, Dr Sheth's, etc.), Nutraceuticals (Fluence Pharma, BTM Ventures). Multi-brand, asset-light Indian beauty and personal care platform
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 1,920 | 2,067 | 2,392 |
| EBITDA (ex other income) | 137 | 69 | 231 |
| margin % | 7.1 | 3.3 | 9.7 |
| Owners' profit | 112 | 73 | 200 |
| EPS, as reported (₹) | 3.57 | 2.24 | 6.15 |
| ROE % · ROCE % | 10.1 · 12.8 | 6.2 · 7.9 | 14.2 · 17.8 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 |
| Cash from operations | 235 | 102 | 141 |
| Capex | 0 | (17) | (7) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 462 | 518 | 534 | 595 | 1,133 | 602 | 657 | 756 |
| Profit before tax | (24) | 29 | 32 | 56 | 108 | 67 | 82 | 119 |
| Net profit | (19) | 26 | 25 | 41 | 81 | 50 | 69 | 90 |
| EPS (₹) | (0.57) | 0.80 | 0.77 | 1.27 | 2.47 | 1.54 | 2.13 | 2.77 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| GODREJ CONSUMER PRODUCTS | 88,507 | 46.2 | 6.99 | 28.7 | 14.7 | 19.0 | 6.6 | 19.8 |
| DABUR INDIA LTD | 66,702 | 33.8 | 5.65 | 22.3 | 15.8 | 19.8 | 6.6 | 24.3 |
| COLGATE PALMOLIVE LTD. | 48,889 | 36.3 | 30.86 | — | 83.7 | 107.1 | — | 31.3 |
| CUPID LIMITED | 37,644 | 102.9 | 83.50 | 249.5 | 24.0 | 30.3 | — | 40.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · Management to attend Jefferies and JP Morgan investor conferences | board shareholder meetings | low | — | — |
| 11 Sept 2026 · Honasa Consumer to attend Jefferies and JP Morgan investor conferences | board shareholder meetings | low | — | — |
| 8 Sept 2026 · Nishchay Bahl elevated to Chief Business Officer - Offline at Honasa | management changes | medium | — | — |
| 8 Sept 2026 · Nishchay Bahl named Chief Business Officer for offline business | management changes | medium | — | — |
| 4 Sept 2026 · Notice of 10th AGM and e-voting published in newspapers | compliance | minimal | — | — |
| 3 Sept 2026 · Honasa Consumer 10th AGM Notice on Sept 28, 2026 | board shareholder meetings | low | — | — |
| 26 Aug 2026 · TDS communication on maiden ₹3 final dividend for FY26 | corporate actions | low | — | — |
| 25 Aug 2026 · Honasa Consumer calls off Fluence Pharma acquisition | strategic transactions | high | — | — |
| 25 Aug 2026 · Honasa Consumer calls off proposed Fluence Pharma acquisition | strategic transactions | high | — | — |
| 21 Aug 2026 · AGM on Sep 28; final dividend of Rs 3 per share; record date Aug 28 | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| P&G HYGIENE & HEALTH CARE | 24,410 | 30.9 | 32.40 | — | 113.7 | 134.4 | — | 20.1 |
| GILLETTE INDIA LTD | 23,807 | 35.6 | 25.15 | — | 69.1 | 83.4 | — | 29.8 |
| EMAMI LIMITED | 15,893 | 21.2 | 5.44 | 15.3 | 26.5 | 28.4 | 5.6 | 23.5 |
| HONASA CONSUMER LIMITED ◆ | 15,331 | 52.9 | 10.86 | 48.3 | 14.2 | 16.9 | — | 17.6 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 52.9 | 36.3 | 11 of 15 | 29% |
| P/B | 10.9 | 8.7 | 9 of 13 | 33% |
| ROCE | 16.9 | 19.4 | 12 of 16 | 27% |
| ROE | 14.2 | 15.8 | 9 of 13 | 33% |
| Debt / Equity | 0.0 | 0.0 | 1 of 13 | 50% |
| EBITDA margin | 17.6 | 23.5 | 10 of 13 | 25% |
| Revenue growth | 27.0 | 13.4 | 5 of 14 | 69% |
| Profit growth | 118.9 | 9.4 | 2 of 13 | 92% |
| Market cap | 15331 | 11078 | 8 of 16 | 53% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
